Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients
- 1 August 2008
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (8), 2855-2860
- https://doi.org/10.1128/aac.00014-08
Abstract
The pharmacokinetics of miltefosine in leishmaniasis patients are, to a great extent, unknown. We examined and characterized the pharmacokinetics of miltefosine in a group of patients with Old World ( Leishmania major ) cutaneous leishmaniasis. Miltefosine plasma concentrations were determined in samples taken during and up to 5 months after the end of treatment from 31 Dutch military personnel who contracted cutaneous leishmaniasis in Afghanistan and were treated with 150 mg miltefosine/day for 28 days. Samples were analyzed with a validated liquid chromatography-tandem mass spectrometry assay with a lower limit of quantification (LLOQ) of 4 ng/ml. Population pharmacokinetic modeling was performed with nonlinear mixed-effect modeling, using NONMEM. The pharmacokinetics of miltefosine could best be described by an open two-compartment disposition model, with a first elimination half-life of 7.05 days and a terminal elimination half-life of 30.9 days. The median concentration in the last week of treatment (days 22 to 28) was 30,800 ng/ml. The maximum duration of follow-up was 202 days after the start of treatment. All analyzed samples contained a concentration above the LLOQ. Miltefosine is eliminated from the body much slower than previously thought and is therefore still detectable in human plasma samples taken 5 to 6 months after the end of treatment. The presence of subtherapeutic miltefosine concentrations in the blood beyond 5 months after treatment might contribute to the selection of resistant parasites, and moreover, the measures for preventing the teratogenic risks of miltefosine treatment should be reconsidered.Keywords
This publication has 30 references indexed in Scilit:
- Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2008
- Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in IndiaClinical Infectious Diseases, 2004
- Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)International Journal of Antimicrobial Agents, 2003
- Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasisThe Pediatric Infectious Disease Journal, 2003
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002
- Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin BActa Tropica, 2001
- Drug resistance in Indian visceral leishmaniasisTropical Medicine & International Health, 2001
- A policy for leishmaniasis with respect to the prevention and control of drug resistanceTropical Medicine & International Health, 2001
- Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral AgentClinical Infectious Diseases, 2001
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999